Holocene Advisors’s Apogee Therapeutics APGE Stock Holding History

Holocene Advisors’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-57,473	Closed	-$4.84M	–	807
2026 Q1	$4.84M	Buy	+57,473	New	+$4.17M	0.01%	405
2024 Q1	–	Sell	-101,202	Closed	-$2.83M	–	707
2023 Q4	$2.83M	Hold	101,202	–	–	0.01%	463
2023 Q3	$2.16M	Buy	+101,202	New	+$2.23M	0.01%	549

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Holocene Advisors's APGE Position: Q2 2026 in Review

Holocene Advisors sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 57,473 shares — an estimated $4.84M sold.

Holocene Advisors first reported a position in APGE in Q3 2023 and held it in 3 quarters. The position peaked at $4.84M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Holocene Advisors reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Holocene Advisors sold 57,473 Apogee Therapeutics shares in Q2 2026, an estimated $4.84M.
Holocene Advisors first reported a position in Apogee Therapeutics in Q3 2023 and held it in 3 quarters.
Holocene Advisors's Apogee Therapeutics position peaked at $4.84M in Q1 2026.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.